A new study [1] shows that patients with non-alcoholic fatty liver disease (NAFLD) are at higher risk of cardiovascular disease, because NAFLD prompts the over-production of a class of proteins that cause inflammation and damage to their blood vessels. Click to read more.
Patients with non-alcoholic fatty liver disease (NAFLD) are at higher risk of cardiovascular disease, because NAFLD prompts the over-production of a class of proteins that cause inflammation and damage to their blood vessels.
A*STAR, NHCS, NUS, and Novo Nordisk to Collaborate on Cardiovascular Disease Research dicardiology.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dicardiology.com Daily Mail and Mail on Sunday newspapers.
The Agency for Science, Technology and Research's Genome Institute of Singapore and Bioinformatics Institute, as well as the National Heart Centre Singapore, National University of Singapore, and pharmaceutical company Novo Nordisk have signed an agreement to study the mechanisms underlying cardiovascular disease progression-; especially the condition called heart failure with preserved ejection fraction (HFpEF).